The question of Traumakine’s value is relevant when funds are being raised, i.e., now.
The DoD has studied it via animal trials, for example, but there is no information on the current status. I haven’t seen any negative results from it, though. A patent was just granted. Something could be gained from battlefield injuries and multi-organ failure caused by tourniquets, but very little.
In COVID, Phase 3 went wrong because the use of corticosteroids could not be controlled; would it be manageable today in, for instance, similar lung inflammation caused by influenza? That would require expensive Phase 3 trials again.
More could be gained from protecting blood vessels in ICU conditions and preventing CAR-T cytokine storms; this would require trials, e.g., the IIT that was about to start, but they would have wanted financial support for it. Compared to Bex’s potential, it is indeed a side asset, and since our money had to be saved, it’s being saved.
It might be some kind of a neglected backup asset. Or it could be presented as such. Besides speculation, it would be nice to hear what they think about it. Based on current communications, apparently not much. It isn’t even mentioned as a drug candidate on Faron’s website anymore.